DexCom, Inc. Aktie News

These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM business, and its addressable market is expanding.

LOS ANGELES , Nov. 21, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  DexCom, Inc. ("DexCom " or "the Company") (NASDAQ: DXCM ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of DXCM during the class per...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will a...

LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of DXCM during the class peri...

NEW YORK , Nov. 20, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline. So what: If you purchased DexCom securities during the Class Period you may be entitled...

ERLANGER, Ky., Nov. 19, 2025 (GLOBE NEWSWIRE) -- In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership with Dexcom, the global leader in glucose biosensing. As part of the partnership, Dexcom will support DAV's mission and collaborate on a diabetes resource page for veterans and their caregivers. This will be Dexcom's first p...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate pe...

Downtrodden names expected to come roaring back include Adobe, Block and Salesforce.